Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 92333-25-0 | MDL No. : | MFCD00012825 |
Formula : | C7H7ClN2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | UBYQSEXKPQZPCN-UHFFFAOYSA-N |
M.W : | 154.60 g/mol | Pubchem ID : | 12396608 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.14 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 40.72 |
TPSA : | 36.68 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.25 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 1.4 |
Log Po/w (WLOGP) : | 1.95 |
Log Po/w (MLOGP) : | 0.46 |
Log Po/w (SILICOS-IT) : | 1.65 |
Consensus Log Po/w : | 1.09 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.06 |
Solubility : | 1.35 mg/ml ; 0.00874 mol/l |
Class : | Soluble |
Log S (Ali) : | -1.77 |
Solubility : | 2.6 mg/ml ; 0.0168 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -2.46 |
Solubility : | 0.531 mg/ml ; 0.00344 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.17 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302+H312+H332-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
15% | Stage #1: pyridin-4-ylacetonitrile hydrochloride With sodium hydride In dimethyl sulfoxide at 23℃; for 0.5h; Stage #2: nitrogen mustard In dimethyl sulfoxide at 65℃; | G.1 1. Preparation of l-methyl-4-(pyridin-4-yl)piperidine-4-carbonitrile[00185] A solution of 4-pyridyl acetonitrile hydrochloride (1.Og, 6.47 mmol) in DMSO (8 mL) was treated with sodium hydride (0.735 g, 29.11 mmol) portionwise. The resulting suspension was stirred at 23°C for 30 minutes. 2-Chloro-N-(2- chloroethyl)-N-methylethanamine (1.37g, 7.11 mmol) was then slowly added over 5 minutes, then the suspension was heated at 65°C overnight. The reaction was then diluted with IN hydrochloric acid and washed with ethyl acetate (2x). The aqueous phase was basified with 5ν sodium hydroxide and extracted with ethyl acetate (3x). The combined extracts were washed with water (5x), dried over anhydrous magnesium sulfate, filtered and concentrated to give an oil (0.20Og, 15%) which was used as such for the next reaction. 1H NMR (400 MHz, CDCl3) δ ppm: 2.10-2.17 (3 H, m), 2.31 -2.37 (IH, m), 2.42 (3H, s), 2.47-2.57 (2H, m), 3.01 (2G, d, j=12.6 Hz), 7.45 (2H, dd, J=4.55 and 1.52 Hz), 8.68 (2H, dd, J=4.55 and 1.77 Hz). |
[ 79757-31-6 ]
2-Methyl-2-(pyridin-4-yl)propanenitrile
Similarity: 0.88
[ 1214375-64-0 ]
2-(3,5-Di(pyridin-4-yl)phenyl)acetonitrile
Similarity: 0.85
[ 112170-33-9 ]
2-(4-(Pyridin-4-yl)phenyl)acetonitrile
Similarity: 0.85
[ 79757-31-6 ]
2-Methyl-2-(pyridin-4-yl)propanenitrile
Similarity: 0.88
[ 1214375-64-0 ]
2-(3,5-Di(pyridin-4-yl)phenyl)acetonitrile
Similarity: 0.85
[ 112170-33-9 ]
2-(4-(Pyridin-4-yl)phenyl)acetonitrile
Similarity: 0.85